《盈警響號》君實生物(01877.HK)收入減少 預計全年虧損擴至24億人民幣
君實生物(01877.HK)發盈警,預計2022年度淨虧損約23.96億人民幣(下同),較上一年度增加16.74億元,增幅232%。主要因公司對在研項目及儲備研發項目的投入處於較高水平,營業收入扣除產品推廣、日常運營等支出後尚不能完全覆蓋研發投入。
全年營業收入預計減少64%至14.46億元,主要是上期新冠中和抗體埃特司韋單抗(JS016/LY-CoV016)產生了海外市場大額技術許可收入及特許權收入。全年研發費用預計增加14.3%至23.64億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.